0001104659-23-003471.txt : 20230112 0001104659-23-003471.hdr.sgml : 20230112 20230112171317 ACCESSION NUMBER: 0001104659-23-003471 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230112 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events FILED AS OF DATE: 20230112 DATE AS OF CHANGE: 20230112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VYNE Therapeutics Inc. CENTRAL INDEX KEY: 0001566044 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453757789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38356 FILM NUMBER: 23526582 BUSINESS ADDRESS: STREET 1: 685 ROUTE 202/206, SUITE 301A CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 800-775-7936 MAIL ADDRESS: STREET 1: 685 ROUTE 202/206, SUITE 301A CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Menlo Therapeutics Inc. DATE OF NAME CHANGE: 20180201 FORMER COMPANY: FORMER CONFORMED NAME: Menlo Therapeutics, Inc. DATE OF NAME CHANGE: 20170728 FORMER COMPANY: FORMER CONFORMED NAME: Tigercat Pharma, Inc. DATE OF NAME CHANGE: 20130104 8-K 1 tm233167d1_8k.htm FORM 8-K
0001566044 false 0001566044 2023-01-12 2023-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) January 12, 2023


VYNE Therapeutics Inc.

(Exact name of registrant as specified in its charter)


Delaware   001-38356   45-3757789

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification Number)


685 Route 202/206, Suite 301A

Bridgewater, New Jersey 08807

(Address of principal executive offices, including Zip Code)


(800) 775-7936

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading

Name of each exchange

on which registered

Common Stock, $0.0001 par value   VYNE   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x






Item 2.02. Results of Operations and Financial Condition.


The information included in Item 8.01 of this Current Report on Form 8-K is incorporated in this Item 2.02 by reference.


Item 5.07. Submission of Matters to a Vote of Security Holders.


On January 12, 2023, VYNE Therapeutics Inc. (the “Company”) convened a special meeting of stockholders (the “Special Meeting”) to adopt and approve a proposed amendment to the Company’s Amended and Restated Certificate of Incorporation and authorize the Board of Directors of the Company (the “Board”), in its sole discretion, to effect a reverse stock split of the outstanding shares of common stock of the Company (the “Common Stock”) at any time on or before the one year anniversary of the Special Meeting, at a reverse stock split ratio ranging from 1-for-10 to 1-for-25, as determined by the Board at a later date (the “Reverse Stock Split Proposal”).


At the Special Meeting, the stockholders voted on the Reverse Stock Split Proposal, which is described as Proposal 1 in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 25, 2022 (the “Proxy Statement”), and a proposal to adjourn the Special Meeting if necessary to solicit additional proxies if there are insufficient votes to adopt the Reverse Stock Split Proposal, as described in Proposal 2 in the Proxy Statement (the “Adjournment Proposal,” and together with the Reverse Stock Split Proposal, the “Proposals”). Each of the 58,035,827 shares of Common Stock outstanding on the record date for the Special Meeting and present either by attendance or by proxy was entitled to one vote per share on the Proposals, and each of the 3,000 shares of Series A Preferred Stock of the Company (“Series A Preferred”), constituting 100% of the outstanding shares of Series A Preferred, outstanding on the record date for the Special Meeting, all of which were present by proxy at the Special Meeting, were entitled to 1,000,000 votes per share with respect to the Proposals. As described in the Proxy Statement, shares of Series A Preferred may only vote on the Proposals, vote with the Common Stock as a single class, and are, to the extent cast, voted in the same proportion as the aggregate shares of Common Stock (excluding abstentions and any shares of Common Stock that are not voted) are voted on the Proposals.


The following is a summary of the voting results:


Proposal 1: Reverse Stock Split Proposal. With respect to the shares of Common Stock present in person or by proxy at the Special Meeting, votes “For” were 24,230,441; votes “Against” were 3,711,239; votes abstaining or withheld were 204,263, and there were no broker non-votes. Including the votes of the Series A Preferred, voting results were as follows:


Votes For  Votes Against  Abstentions / Withheld
2,625,767,750  402,173,930  204,263


The Reverse Stock Split Proposal was approved.


Proposal 2: Adjournment Proposal. With respect to the shares of Common Stock present in person or by proxy at the Special Meeting, votes “For” were 24,029,283; votes “Against” were 3,693,414; votes abstaining or withheld were 423,246, and there were no broker non-votes. Including the votes of the Series A Preferred, voting results were as follows:


Votes For  Votes Against  Abstentions / Withheld
2,624,348,039  403,374,658  423,246


The Adjournment Proposal was approved.





Item 7.01. Regulation FD Disclosure.


On January 12, 2023, the Company delivered a notice of redemption to the holder of the Series A Preferred. The Series A Preferred will be redeemed on January 17, 2023 (the “Redemption Date”) for an aggregate of $360,000 to be paid to the sole holder of the Series A Preferred. On the Redemption Date, the Company will file a Certificate of Elimination (the “Certificate”) with the Secretary of State of the State of Delaware with respect to the Series A Preferred. The Certificate will (i) eliminate the previous designation of 3,000 shares of Series A Preferred from the Company’s Amended and Restated Certificate of Incorporation and (ii) cause such shares of Series A Preferred to resume their status as authorized but unissued and non-designated shares of preferred stock.


Item 8.01. Other Events.


On January 12, 2023, the Company received the $5.0 million deferred payment from Journey Medical Corporation pursuant to the Asset Purchase Agreement, dated as of January 12, 2022. As of December 31, 2022, the Company had approximately $35.9 million of cash and cash equivalents on a pro forma basis after giving effect to the receipt of this deferred payment. The preliminary financial information set forth in this Current Report on Form 8-K is unaudited and subject to the completion of the Company’s audit process and is subject to change. The estimated preliminary results included in this report should not be viewed as a substitute for the Company’s annual financial statements prepared in accordance with U.S. generally accepted accounting principles.







Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: January 12, 2023 By: /s/ Mutya Harsch

Mutya Harsch

Chief Legal Officer and General Counsel



EX-101.SCH 2 vyne-20230112.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 vyne-20230112_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 vyne-20230112_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Jan. 12, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 12, 2023
Entity File Number 001-38356
Entity Registrant Name VYNE Therapeutics Inc.
Entity Central Index Key 0001566044
Entity Tax Identification Number 45-3757789
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 685 Route 202/206
Entity Address, Address Line Two Suite 301A
Entity Address, City or Town Bridgewater
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08807
City Area Code 800
Local Phone Number 775-7936
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol VYNE
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 6 tm233167d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001566044 2023-01-12 2023-01-12 iso4217:USD shares iso4217:USD shares 0001566044 false 8-K 2023-01-12 VYNE Therapeutics Inc. DE 001-38356 45-3757789 685 Route 202/206 Suite 301A Bridgewater NJ 08807 800 775-7936 false false false false Common Stock, $0.0001 par value VYNE NASDAQ true true EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://menlotherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm233167d1_8k.htm vyne-20230112.xsd vyne-20230112_lab.xml vyne-20230112_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm233167d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm233167d1_8k.htm" ] }, "labelLink": { "local": [ "vyne-20230112_lab.xml" ] }, "presentationLink": { "local": [ "vyne-20230112_pre.xml" ] }, "schema": { "local": [ "vyne-20230112.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vyne", "nsuri": "http://menlotherapeutics.com/20230112", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm233167d1_8k.htm", "contextRef": "From2023-01-12to2023-01-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://menlotherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm233167d1_8k.htm", "contextRef": "From2023-01-12to2023-01-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://menlotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001104659-23-003471-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-003471-xbrl.zip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end